HDAC Cancer Research Results

HDAC, Histone deacetylases: Click to Expand ⟱
Source:
Type:
Enzymes involved in regulating gene expression by removing acetyl groups from histones, the proteins around which DNA is wrapped.
-Many cancers exhibit altered expression levels of HDACs, which can contribute to the dysregulation of genes involved in cell growth, survival, and differentiation.
-HDACs can repress the expression of tumor suppressor genes, leading to uncontrolled cell proliferation and survival. This repression can be a key factor in the development and progression of cancer.
-HDAC inhibitors (HDACi) have been developed and are being investigated for their ability to reactivate silenced genes, induce cell cycle arrest, and promote apoptosis in cancer cells.
-HDAC1, HDAC2): Often overexpressed in various cancers, including breast, prostate, and colorectal cancers. Their overexpression is associated with poor prognosis.
-HDAC4, HDAC5): These may have both oncogenic and tumor-suppressive roles depending on the context and cancer type.
-While HDACs are not classified as traditional oncogenes, their overexpression and activity can contribute to oncogenic processes.
-HDAC inhibitor works by preventing the removal of acetyl groups from histones, thereby modulating gene expression, influencing cell behavior, and potentially reversing aberrant gene silencing seen in various diseases.
-HDAC inhibitors can help reactivate these genes, thereby inhibiting growth and inducing apoptosis in cancer cells.
Var, Various Cancer: Click to Expand ⟱
Cyclooxygenase (COX)-2 overexpression has been noted in various cancers. PI3Ks/AKT pathways are over-activated in several types of cancers.
EGFR altered activity has been noted in various pathological conditions. However, its regulation is an important step in the inhibition of cancer. In this regard, EGCG shows a pivotal role in the inhibition of EGFR activity.
Activating protein-1 transcription factor has been associated with pathogenesis including cancer.
Activation of the sonic hedgehog (Shh) pathway is required for the growth of numerous tissues and organs and recent evidence indicates that this pathway is often recruited to stimulate growth of cancer stem cells (CSCs) and to orchestrate the reprogramming of cancer cells via epithelial mesenchymal transition (EMT). Increased expression of Nanog has been associated with the aggressive nature of certain cancers, highlighting its role in promoting cancer stem cell characteristics.
The aberrant hedgehog (Hh)/GLI signaling pathway causes the formation and progression of a variety of tumors.
The process of cell apoptosis is often accompanied by the destruction of mitochondrial transmembrane potential, which is widely regarded as one of the earliest events in the process of cell apoptosis.
Human malignancies frequently exhibit mutations in the TGF-β pathway, and overactivation of this system is linked to tumor growth by promoting angiogenesis and inhibiting the innate and adaptive antitumor immune responses50.
Several studies have demonstrated that high cyclin D1 expression was observed in cancers including breast, lung, prostate, lymph node and colorectal cancers [23–25].
The oncogene c-myc, which is frequently over-expressed in cancer cells, is involved in the transactivation of most of the glycolytic enzymes including lactate dehydrogenase A (LDHA) and the glucose transporter GLUT1 [51,52]. Thus, c-myc activation is a likely candidate to promote the enhanced glucose uptake and lactate release in the proliferating cancer cell.
Vimentin is overexpressed in various epithelial cancers, including prostate cancer, gastrointestinal tumors, tumors of the central nervous system, breast cancer, malignant melanoma, and lung cancer. Vimentin’s overexpression in cancer correlates well with accelerated tumor growth, invasion, and poor prognosis; however, the role of vimentin in cancer progression remains obscure.
Heat shock proteins (HSPs) are normally induced under environmental stress to serve as chaperones for maintenance of correct protein folding but they are often overexpressed in many cancers, including breast cancer.
Since NQO1 is highly expressed in many solid tumors, including via upregulation of Nrf2, the design of compounds activated by NQO1 and NQO1-targeted drug delivery have been active areas of research.
Since increased Nrf2 gene expression is one of the main mechanisms of cancer cells in resisting chemotherapeutic drugs and survival in oxidative conditions; finding compounds with the ability to suppress Nrf2 gene expression with minimum side effects can be considered an important strategy for increasing the sensitivity of cancer cells to chemotherapy.
Overexpression of c-met stimulates proliferation, migration and invasion in various types of cancer including prostate cancer.
Overexpression of TGFα and EGFR by many carcinomas correlates with the development of cancer metastasis, resistance to chemotherapy and poor prognosis.
More than 50% of human cancers have a mutated nonfunctional p53.


Scientific Papers found: Click to Expand⟱
5271- 3BP,    The anticancer agent 3-bromopyruvate: a simple but powerful molecule taken from the lab to the bedside
- Review, Var, NA
selectivity↑, selectivity↑, ATP↓, Glycolysis↓, HK2↓, mt-OXPHOS↓, GAPDH↓, mtDam↑, GSH↓, ROS↑, ER Stress↑, TumAuto↑, LC3‑Ⅱ/LC3‑Ⅰ↑, p62↓, Akt↓, HDAC↓, TumCA↑, Bcl-2↓, cMyc↓, Casp3↑, Cyt‑c↑, Mcl-1↓, PARP↓, ChemoSen↑,
2639- Api,    Plant flavone apigenin: An emerging anticancer agent
- Review, Var, NA
*antiOx↑, *Inflam↓, AntiCan↑, ChemoSen↑, BioEnh↑, chemoPv↑, IL6↓, STAT3↓, NF-kB↓, IL8↓, eff↝, Akt↓, PI3K↓, HER2/EBBR2↓, cycD1/CCND1↓, CycD3↓, p27↑, FOXO3↑, STAT3↓, MMP2↓, MMP9↓, VEGF↓, Twist↓, MMP↓, ROS↑, NADPH↑, NRF2↓, SOD↓, COX2↓, p38↑, Telomerase↓, HDAC↓, HDAC1↓, HDAC3↓, Hif1a↓, angioG↓, uPA↓, Ca+2↑, Bax:Bcl2↑, Cyt‑c↑, Casp9↑, Casp12↑, Casp3↑, cl‑PARP↑, E-cadherin↑, β-catenin/ZEB1↓, cMyc↓, CDK4↓, CDK2↓, CDK6↓, IGF-1↓, CK2↓, CSCs↓, FAK↓, Gli↓, GLUT1↓,
2664- Api,    Progress in discovery and development of natural inhibitors of histone deacetylases (HDACs) as anti-cancer agents
- Review, Var, NA
HDAC↓,
5449- ATV,    Pleiotropic effects of statins: A focus on cancer
- NA, Var, NA
lipid-P↓, TumCG↓, Apoptosis↑, ChemoSen↑, RAS↓, HMG-CoA↓, HMGCR↓, LDL↓, toxicity↓, Risk↓, P21↑, HDAC↓, Bcl-2↓, BAX↑, BIM↑, Casp↑, cl‑PARP↑, MMP↓, ROS↑, angioG↓, TumMeta↓, PTEN↑, eff↑, OS↑, Remission↑,
2697- BBR,    Structural exploration of common pharmacophore based berberine derivatives as novel histone deacetylase inhibitor targeting HDACs enzymes
- Analysis, Var, NA
HDAC↓,
2764- BetA,    In silico profiling of histone deacetylase inhibitory activity of compounds isolated from Cajanus cajan
- Analysis, Var, NA
HDAC↓,
3523- Bor,    Design, Synthesis, and Biological Activity of Boronic Acid-Based Histone Deacetylase Inhibitors
- in-vitro, Var, NA
HDAC↓,
3522- Bor,    The Boron Advantage: The Evolution and Diversification of Boron’s Applications in Medicinal Chemistry
- Review, Var, NA
Hif1a↓, HDAC↓, *CXCR2↑, ROS↑,
696- Bor,    Nothing Boring About Boron
- Review, Var, NA
*hs-CRP↓, *TNF-α↓, *SOD↑, *Catalase↑, *GPx↑, *cognitive↑, *memory↑, *Risk↓, *SAM-e↑, *NAD↝, *ATP↝, *Ca+2↝, HDAC↓, TumVol↓, IGF-1↓, PSA↓, Cyc↓, TumCMig↓, *serineP↓, HIF-1↓, *ChemoSideEff↓, *VitD↑, *Mag↑, *eff↑, Risk↓, *Inflam↓, *neuroP↑, *Calcium↑, *BMD↑, *chemoP↑, AntiCan↑, *Dose↑, *Dose↝, *BMPs↑, *testos↑, angioG↓, Apoptosis↑, *selectivity↑, *chemoPv↑,
5745- Buty,    Microbial Oncotarget: Bacterial-Produced Butyrate, Chemoprevention and Warburg Effect
- Review, Var, NA
selectivity↑, HDAC↓, TumCP↓, Apoptosis↑, Warburg↓, chemoPv↑,
5743- Buty,    Regulation of Intestinal Butyrate Transporters by Oxidative and Inflammatory Status
- Review, Var, NA
*GutMicro↑, *other↑, *Inflam↓, *ROS↓, AntiCan↑, HCAR2↑, HDAC↓,
5742- Buty,    Butyrate: A Double-Edged Sword for Health?
- Review, Var, NA
HCAR2↑, Inflam↓, HDAC↓, *IFN-γ↓, *TNF-α↓, *IL1β↓, *IL6↓, *IL8↓, *IL10↑, *TNF-β↑, *NF-kB↓, *ROS↓, PPARγ↓, Weight↓,
5739- Buty,    Butyrate as a promising therapeutic target in cancer: From pathogenesis to clinic (Review)
- Review, Var, NA
GutMicro↑, *Inflam↓, *IL6↓, *TNF-α↓, *IL17↓, *IL10↑, *ROS↝, COX2↓, NLRP3↓, Imm↑, HDAC↓, TumCCA↑, Apoptosis↑, ROS↑, Casp↑, mtDam↑, Cyt‑c↑, eff↑, chemoP↑, ChemoSen↑, eff↑, RadioS↑, HCAR2↑,
2784- CHr,    Chrysin targets aberrant molecular signatures and pathways in carcinogenesis (Review)
- Review, Var, NA
Apoptosis↑, TumCMig↓, *toxicity↝, ChemoSen↑, *BioAv↓, Dose↝, neuroP↑, *P450↓, *ROS↓, *HDL↑, *GSTs↑, *SOD↑, *Catalase↑, *MAPK↓, *NF-kB↓, *PTEN↑, *VEGF↑, ROS↑, MMP↓, Ca+2↑, selectivity↑, PCNA↓, Twist↓, EMT↓, CDKN1C↑, p‑STAT3↑, MMP2↓, MMP9↓, eff↑, cycD1/CCND1↓, hTERT/TERT↓, CLDN1↓, TumVol↓, OS↑, COX2↓, eff↑, CDK2↓, CDK4↓, selectivity↑, TumCCA↑, E-cadherin↑, HK2↓, HDAC↓,
2785- CHr,    Emerging cellular and molecular mechanisms underlying anticancer indications of chrysin
- Review, Var, NA
*NF-kB↓, *COX2↓, *iNOS↓, angioG↓, TOP1↓, HDAC↓, TNF-α↓, IL1β↓, cardioP↑, RenoP↑, neuroP↑, LDL↓, BioAv↑, eff↑, cycD1/CCND1↓, hTERT/TERT↓, MMP-10↓, Akt↓, STAT3↓, VEGF↓, EGFR↓, Snail↓, Slug↓, Vim↓, E-cadherin↑, eff↑, TET1↑, ROS↑, mTOR↓, PPARα↓, ER Stress↑, Ca+2↑, ERK↓, MMP↑, Cyt‑c↑, Casp3↑, HK2↓, NRF2↓, HO-1↓, MMP2↓, MMP9↓, Fibronectin↓, GRP78/BiP↑, XBP-1↓, p‑eIF2α↑, *AST↓, ALAT↓, ALP↓, LDH↓, COX2↑, Bcl-xL↓, IL6↓, PGE2↓, iNOS↓, DNAdam↑, UPR↑, Hif1a↓, EMT↓, Twist↓, lipid-P↑, CLDN1↓, PDK1↓, IL10↓, TLR4↓, NOTCH1↑, PARP↑, Mcl-1↓, XIAP↓,
4826- CUR,    The Bright Side of Curcumin: A Narrative Review of Its Therapeutic Potential in Cancer Management
- Review, Var, NA
*antiOx↑, *Inflam↑, *ROS↓, Apoptosis↑, TumCP↓, BioAv↓, Half-Life↓, eff↑, TumCCA↑, BAX↑, Bak↑, PUMA↑, BIM↑, NOXA↑, TRAIL↑, Bcl-2↓, Bcl-xL↓, survivin↓, XIAP↓, cMyc↓, Casp↑, NF-kB↓, STAT3↓, AP-1↓, angioG↓, TumMeta↑, VEGF↓, MMPs↓, DNMTs↓, HDAC↓, ROS↑,
1863- dietFMD,  Chemo,    Effect of fasting on cancer: A narrative review of scientific evidence
- Review, Var, NA
eff↑, ChemoSideEff↓, ChemoSen↑, Insulin↓, HDAC↓, IGF-1↓, STAT5↓, BG↓, MAPK↓, HO-1↓, ATG3↑, Beclin-1↑, p62↑, SIRT1↑, LAMP2↑, OXPHOS↑, ROS↑, P53↑, DNAdam↑, TumCD↑, ATP↑, Treg lymp↓, M2 MC↓, CD8+↑, Glycolysis↓, GutMicro↑, GutMicro↑, Warburg↓, Dose↝,
3238- EGCG,    Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications
- Review, Var, NA
Telomerase↓, DNMTs↓, cycD1/CCND1↓, cycE/CCNE↓, CDK2↓, CDK4↓, CDK6↓, HATs↓, HDAC↓, selectivity↑, uPA↓, NF-kB↓, TNF-α↓, *ROS↓, *antiOx↑, Hif1a↓, VEGF↓, MMP2↓, MMP9↓, FAK↓, TIMP2↑, Mcl-1↓, survivin↓, XIAP↓, PCNA↓, p16↑, P21↑, p27↑, pRB↑, P53↑, MDM2↑, ROS↑, Casp3↑, Casp8↑, Casp9↑, Cyt‑c↑, Diablo↑, BAX⇅, cl‑PPARα↓, PDGF↓, EGFR↓, FOXO↑, AP-1↓, JNK↓, COX2↓, angioG↓,
2868- HNK,    Honokiol: A review of its pharmacological potential and therapeutic insights
- Review, Var, NA - Review, Sepsis, NA
*P-gp↓, *ROS↓, *TNF-α↓, *IL10↓, *IL6↓, eIF2α↑, CHOP↑, GRP78/BiP↑, BAX↑, cl‑Casp9↑, p‑PERK↑, ER Stress↑, Apoptosis↑, MMPs↓, cFLIP↓, CXCR4↓, Twist↓, HDAC↓, BMPs↑, p‑STAT3↓, mTOR↓, EGFR↓, NF-kB↓, Shh↓, VEGF↓, tumCV↓, TumCMig↓, TumCI↓, ERK↓, Akt↓, Bcl-2↓, Nestin↓, CD133↓, p‑cMET↑, RAS↑, chemoP↑, *NRF2↑, *NADPH↓, *p‑Rac1↓, *ROS↓, *IKKα↑, *NF-kB↓, *COX2↓, *PGE2↓, *Casp3↓, *hepatoP↑, *antiOx↑, *GSH↑, *Catalase↑, *RenoP↑, *ALP↓, *AST↓, *ALAT↓, *neuroP↑, *cardioP↑, *HO-1↑, *Inflam↓,
2864- HNK,    Honokiol: A Review of Its Anticancer Potential and Mechanisms
- Review, Var, NA
TumCCA↑, CDK2↓, EMT↓, MMPs↓, AMPK↑, TumCI↓, TumCMig↓, TumMeta↓, VEGFR2↓, *antiOx↑, *Inflam↓, *BBB↑, *neuroP↑, *ROS↓, Dose↝, selectivity↑, Casp3↑, Casp9↑, NOTCH1↓, cycD1/CCND1↓, cMyc↓, P21?, DR5↑, cl‑PARP↑, P53↑, Mcl-1↑, p65↓, NF-kB↓, ROS↑, JNK↑, NRF2↑, cJun↑, EF-1α↓, MAPK↓, PI3K↓, mTORC1↓, CSCs↓, OCT4↓, Nanog↓, SOX4↓, STAT3↓, CDK4↓, p‑RB1↓, PGE2↓, COX2↓, β-catenin/ZEB1↑, IKKα↓, HDAC↓, HATs↑, H3↑, H4↑, LC3II↑, c-Raf↓, SIRT3↑, Hif1a↓, ER Stress↑, GRP78/BiP↑, cl‑CHOP↑, MMP↓, PCNA↓, Zeb1↓, NOTCH3↓, CD133↓, Nestin↓, ATG5↑, ATG7↑, survivin↓, ChemoSen↑, SOX2↓, OS↑, P-gp↓, Half-Life↓, Half-Life↝, eff↑, BioAv↓,
2919- LT,    Luteolin as a potential therapeutic candidate for lung cancer: Emerging preclinical evidence
- Review, Var, NA
RadioS↑, ChemoSen↑, chemoP↑, *lipid-P↓, *Catalase↑, *SOD↑, *GPx↑, *GSTs↑, *GSH↑, *TNF-α↓, *IL1β↓, *Casp3↓, *IL10↑, NRF2↓, HO-1↓, NQO1↓, GSH↓, MET↓, p‑MET↓, p‑Akt↓, HGF/c-Met↓, NF-kB↓, Bcl-2↓, SOD2↓, Casp8↑, Casp3↑, PARP↑, MAPK↓, NLRP3↓, ASC↓, Casp1↓, IL6↓, IKKα↓, p‑p65↓, p‑p38↑, MMP2↓, ICAM-1↓, EGFR↑, p‑PI3K↓, E-cadherin↓, ZO-1↑, N-cadherin↓, CLDN1↓, β-catenin/ZEB1↓, Snail↓, Vim↑, ITGB1↓, FAK↓, p‑Src↓, Rac1↓, Cdc42↓, Rho↓, PCNA↓, Tyro3↓, AXL↓, CEA↓, NSE↓, SOD↓, Catalase↓, GPx↓, GSR↓, GSTs↓, GSH↓, VitE↓, VitC↓, CYP1A1↓, cFos↑, AR↓, AIF↑, p‑STAT6↓, p‑MDM2↓, NOTCH1↓, VEGF↓, H3↓, H4↓, HDAC↓, SIRT1↓, ROS↑, DR5↑, Cyt‑c↑, p‑JNK↑, PTEN↓, mTOR↓, CD34↓, FasL↑, Fas↑, XIAP↓, p‑eIF2α↑, CHOP↑, LC3II↑, PD-1↓, STAT3↓, IL2↑, EMT↓, cachexia↓, BioAv↑, *Half-Life↝, *eff↑,
2027- PB,    Phase I dose escalation clinical trial of phenylbutyrate sodium administered twice daily to patients with advanced solid tumors
- Trial, Var, NA
TumCG↓, Dose↝, toxicity↓, Dose↝, HDAC↓, OS↑,
2028- PB,    Potential of Phenylbutyrate as Adjuvant Chemotherapy: An Overview of Cellular and Molecular Anticancer Mechanisms
- Review, Var, NA
HDAC↓, TumCCA↑, P21↑, Dose↝, Telomerase↓, IGFBP3↑, p‑p38↑, JNK↑, ERK↑, BAX↑, Casp3↑, Bcl-2↓, Cyt‑c↝, FAK↓, survivin↓, VEGF↓, angioG↓, DNArepair↓, TumMeta↓, HSP27↑, ASK1↑, ROS↑, eff↑, ER Stress↓, GRP78/BiP↓, CHOP↑, AR↓, other?,
2029- PB,    Phenylbutyric Acid: simple structure - multiple effects
- Review, Var, NA
NH3↓, HDAC↓, ChemChap↑,
2049- PB,    Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors
- Review, Var, NA
HDAC↓, ac‑H3↑, ac‑H4↑, ac‑H3↑, eff↝, toxicity↓,
1660- PBG,    Emerging Adjuvant Therapy for Cancer: Propolis and its Constituents
- Review, Var, NA
MMPs↓, angioG↓, TumMeta↓, TumCCA↑, Apoptosis↑, ChemoSideEff↓, eff∅, HDAC↓, PTEN↑, p‑PTEN↓, p‑Akt↓, Casp3↑, p‑ERK↑, p‑FAK↑, Dose?, Akt↓, GSK‐3β↓, FOXO3↓, eff↑, IL2↑, IL10↑, NF-kB↓, VEGF↓, mtDam↑, ER Stress↑, AST↓, ALAT↓, ALP↓, COX2↓, eff↑, Bax:Bcl2↑,
1666- PBG,    Molecular and Cellular Mechanisms of Propolis and Its Polyphenolic Compounds against Cancer
- Review, Var, NA
ChemoSen↑, TumCCA↑, TumCP↓, Apoptosis↑, antiOx↓, ROS↑, COX2↑, ER(estro)↓, cycA1/CCNA1↓, CycB/CCNB1↓, CDK2↓, P21↑, p27↑, hTERT/TERT↓, HDAC↓, ROS⇅, Dose?, ROS↓, ROS↑, DNAdam↑, ChemoSen↑, LOX1↓, lipid-P↓, NO↑, Igs↑, NK cell↑, MMPs↓, VEGF↓, Hif1a↓, GLUT1↓, HK2↓, selectivity↑, RadioS↑, GlucoseCon↓, lactateProd↓, eff↓, *BioAv↓,
4921- PEITC,    The Potential Use of Phenethyl Isothiocyanate for Cancer Prevention
- Review, Var, NA
antiOx↑, Inflam↓, AntiCan↑, TumCP↓, TumCCA↑, Apoptosis↑, TumAuto↑, HDAC↓, Risk↓,
3360- QC,    Role of Flavonoids as Epigenetic Modulators in Cancer Prevention and Therapy
- Review, Var, NA
HDAC↓, DNMTs↓, HMTs↓, Let-7↑, NOTCH↓,
3368- QC,    The potential anti-cancer effects of quercetin on blood, prostate and lung cancers: An update
- Review, Var, NA
*Inflam↓, *antiOx↑, *AntiCan↑, Casp3↓, p‑Akt↓, p‑mTOR↓, p‑ERK↓, β-catenin/ZEB1↓, Hif1a↓, AntiAg↓, VEGFR2↓, EMT↓, EGFR↓, MMP2↓, MMP↓, TumMeta↓, MMPs↓, Akt↓, Snail↓, N-cadherin↓, Vim↓, E-cadherin↑, STAT3↓, TGF-β↓, ROS↓, P53↑, BAX↑, PKCδ↓, PI3K↓, COX2↓, cFLIP↓, cycD1/CCND1↓, cMyc↓, IL6↓, IL10↓, Cyt‑c↑, TumCCA↑, DNMTs↓, HDAC↓, ac‑H3↑, ac‑H4↑, Diablo↑, Casp3↑, Casp9↑, PARP1↑, eff↑, PTEN↑, VEGF↓, NO↓, iNOS↓, ChemoSen↑, eff↑, eff↑, eff↑, uPA↓, CXCR4↓, CXCL12↓, CLDN2↓, CDK6↓, MMP9↓, TSP-1↑, Ki-67↓, PCNA↓, ROS↑, ER Stress↑,
2555- SFN,    Chemopreventive functions of sulforaphane: A potent inducer of antioxidant enzymes and apoptosis
- Review, Var, NA
chemoPv↑, HDAC↓, TumCCA↑, Apoptosis↑, Mets↑, *NRF2↑, ROS⇅,
2556- SFN,    The role of Sulforaphane in cancer chemoprevention and health benefits: a mini-review
- Review, Var, NA
chemoPv↑, HDAC↓, Hif1a↓, angioG↓, CYP1A1↓, eff↑, BioAv↑,
2554- SFN,    Sulforaphane (SFN): An Isothiocyanate in a Cancer Chemoprevention Paradigm
- Review, Var, NA
Dose↝, chemoPv↑, *NQO1↑, *GSTA1↑, HDAC↓, NF-kB↓,
1730- SFN,    Sulforaphane: An emergent anti-cancer stem cell agent
- Review, Var, NA
BioAv↓, BioAv↑, GSTA1↑, P450↓, TumCCA↑, HDAC↓, P21↑, p27↑, DNMT1↓, DNMT3A↓, cycD1/CCND1↑, DNAdam↑, BAX↑, Cyt‑c↑, Apoptosis↑, ROS↑, AIF↑, CDK1↑, Casp3↑, Casp8↑, Casp9↑, NRF2↑, NF-kB↓, TNF-α↓, IL1β↓, CSCs↓, CD133↓, CD44↓, ALDH↓, Nanog↓, OCT4↓, hTERT/TERT↓, MMP2↓, EMT↓, ALDH1A1↓, Wnt↓, NOTCH↓, ChemoSen↑, *Ki-67↓, *HDAC3↓, *HDAC↓,
1725- SFN,    Anticancer Activity of Sulforaphane: The Epigenetic Mechanisms and the Nrf2 Signaling Pathway
- Review, Var, NA
*toxicity∅, AntiCan↑, antiOx↑, NRF2↑, DNMTs↓, HDAC↓, Hif1a↓, VEGF↓, P21↑, TumCCA↑, ac‑H3↑, ac‑H4↑, DNAdam↑, Dose↝,
1724- SFN,    Sulforaphane: A review of its therapeutic potentials, advances in its nanodelivery, recent patents, and clinical trials
- Review, Var, NA
antiOx↑, NRF2↑, HDAC↓, neuroP↑,
1722- SFN,    Sulforaphane as an anticancer molecule: mechanisms of action, synergistic effects, enhancement of drug safety, and delivery systems
- Review, Var, NA
TumCCA↑, CYP1A1↓, CYP3A4↓, Cyt‑c↑, Casp9↑, Apoptosis↑, ROS↑, MAPK↑, P53↑, BAX↑, ChemoSen↑, HDAC↓, GSH↓, HO-1↑,
1508- SFN,    Nrf2 targeting by sulforaphane: A potential therapy for cancer treatment
- Review, Var, NA
*BioAv↑, HDAC↓, TumCCA↓, eff↓, Wnt↓, β-catenin/ZEB1↓, Casp12?, Bcl-2↓, cl‑PARP↑, Bax:Bcl2↑, IAP1↓, Casp3↑, Casp9↑, Telomerase↓, hTERT/TERT↓, ROS?, DNMTs↓, angioG↓, VEGF↓, Hif1a↓, cMYB↓, MMP1↓, MMP2↓, MMP9↓, ERK↑, E-cadherin↑, CD44↓, MMP2↓, eff↑, IL2↑, IFN-γ↑, IL1β↓, IL6↓, TNF-α↓, NF-kB↓, ERK↓, NRF2↑, RadioS↑, ChemoSideEff↓,
1484- SFN,    Sulforaphane’s Multifaceted Potential: From Neuroprotection to Anticancer Action
- Review, Var, NA - Review, AD, NA
neuroP↑, AntiCan↑, NRF2↑, HDAC↓, eff↑, *ROS↓, neuroP↑, HDAC↓, *toxicity∅, BioAv↑, eff↓, cycD1/CCND1↓, CDK4↓, p‑RB1↓, Glycolysis↓, miR-30a-5p↑, TumCCA↑, TumCG↓, TumMeta↓, eff↑, ChemoSen↑, RadioS↑, CardioT↓, angioG↓, Hif1a↓, VEGF↓, *BioAv?, *Half-Life∅,
3288- SIL,    Silymarin in cancer therapy: Mechanisms of action, protective roles in chemotherapy-induced toxicity, and nanoformulations
- Review, Var, NA
Inflam↓, lipid-P↓, TumMeta↓, angioG↓, chemoP↑, EMT↓, HDAC↓, HATs↑, MMPs↓, uPA↓, PI3K↓, Akt↓, VEGF↓, CD31↓, Hif1a↓, VEGFR2↓, Raf↓, MEK↓, ERK↓, BIM↓, BAX↑, Bcl-2↓, Bcl-xL↓, Casp↑, MAPK↓, P53↑, LC3II↑, mTOR↓, YAP/TEAD↓, *BioAv↓, MMP↓, Cyt‑c↑, PCNA↓, cMyc↓, cycD1/CCND1↓, β-catenin/ZEB1↓, survivin↓, APAF1↑, Casp3↑, MDSCs↓, IL10↓, IL2↑, IFN-γ↑, hepatoP↑, cardioP↑, GSH↑, neuroP↑,
2119- TQ,    Dual properties of Nigella Sativa: anti-oxidant and pro-oxidant
- Review, Var, NA
*ROS↓, ROS↑, chemoP↑, RenoP↑, hepatoP↑, NLRP3↓, neuroP↑, NF-kB↓, P21↑, HDAC↓, Apoptosis↑, TumCP↓, GSH↓, GADD45A↑, GSK‐3β↑,
2102- TQ,    A review on therapeutic potential of Nigella sativa: A miracle herb
- Review, Var, NA
angioG↓, NF-kB↓, PPARγ↓, Bcl-2↓, Bcl-xL↓, MUC4↓, cJun↑, p38↑, P21↑, HDAC↓, *radioP↑, hepatoP↑,
2108- TQ,    Anti-cancer properties and mechanisms of action of thymoquinone, the major active ingredient of Nigella sativa
- Review, Var, NA
HDAC↓, TumCCA↑, cycD1/CCND1↓, p16↑, P53↑, Bax:Bcl2↑, Bcl-xL↓, NF-kB↓, IAP1↓, IAP2↓, XIAP↓, survivin↓, COX2↓, cMyc↓, ROS↑, Casp3↑, cl‑PARP↑, Cyt‑c↑, STAT3↓,
3422- TQ,    Thymoquinone, as a Novel Therapeutic Candidate of Cancers
- Review, Var, NA
selectivity↑, P53↑, PTEN↑, NF-kB↓, PPARγ↓, cMyc↓, Casp↑, *BioAv↓, BioAv↝, eff↑, survivin↓, Bcl-xL↓, Bcl-2↓, Akt↓, BAX↑, cl‑PARP↑, CXCR4↓, MMP9↓, VEGFR2↓, Ki-67↓, COX2↓, JAK2↓, cSrc↓, Apoptosis↑, p‑STAT3↓, cycD1/CCND1↓, Casp3↑, Casp7↑, Casp9↑, N-cadherin↓, Vim↓, Twist↓, E-cadherin↑, ChemoSen↑, eff↑, EMT↓, ROS↑, DNMT1↓, eff↑, EZH2↓, hepatoP↑, Zeb1↓, RadioS↑, HDAC↓, HDAC1↓, HDAC2↓, HDAC3↓, *NAD↑, *SIRT1↑, SIRT1↓, *Inflam↓, *CRP↓, *TNF-α↓, *IL6↓, *IL1β↓, *eff↑, *MDA↓, *NO↓, *GSH↑, *SOD↑, *Catalase↑, *GPx↑, PI3K↓, mTOR↓,
3423- TQ,    Epigenetic role of thymoquinone: impact on cellular mechanism and cancer therapeutics
- Review, Var, NA
AntiCan↑, Inflam↓, hepatoP↑, RenoP↑, BAX↑, Bak↑, Bcl-2↓, Bcl-xL↓, ROS↑, P53↑, PTEN↑, P21↑, p27↑, BRCA1↑, PI3K↓, Akt↓, MAPK↓, ERK↓, p‑ERK↓, MMPs↓, FAK↓, Twist↓, Zeb1↓, EMT↓, TumMeta↓, angioG↓, VEGF↓, HDAC↓, Maspin↑, SIRT1↑, DNMT1↓, DNMT3A↓, HDAC1↓, HDAC4↓,

Showing Research Papers: 1 to 45 of 45

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 45

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress ⓘ

antiOx↓, 1,   antiOx↑, 3,   Catalase↓, 1,   CYP1A1↓, 3,   GPx↓, 1,   GSH↓, 5,   GSH↑, 1,   GSR↓, 1,   GSTA1↑, 1,   GSTs↓, 1,   HO-1↓, 3,   HO-1↑, 1,   lipid-P↓, 3,   lipid-P↑, 1,   Mets↑, 1,   NQO1↓, 1,   NRF2↓, 3,   NRF2↑, 6,   OXPHOS↑, 1,   mt-OXPHOS↓, 1,   ROS?, 1,   ROS↓, 2,   ROS↑, 22,   ROS⇅, 2,   SIRT3↑, 1,   SOD↓, 2,   SOD2↓, 1,   VitC↓, 1,   VitE↓, 1,  

Mitochondria & Bioenergetics ⓘ

AIF↑, 2,   ATP↓, 1,   ATP↑, 1,   Insulin↓, 1,   MEK↓, 1,   MMP↓, 6,   MMP↑, 1,   mtDam↑, 3,   Raf↓, 1,   c-Raf↓, 1,   XIAP↓, 5,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 2,   AMPK↑, 1,   ATG7↑, 1,   cMyc↓, 8,   CYP3A4↓, 1,   GAPDH↓, 1,   GlucoseCon↓, 1,   Glycolysis↓, 3,   HK2↓, 4,   HMG-CoA↓, 1,   lactateProd↓, 1,   LDH↓, 1,   LDL↓, 2,   NADPH↑, 1,   NH3↓, 1,   PDK1↓, 1,   PPARα↓, 1,   cl‑PPARα↓, 1,   PPARγ↓, 3,   SIRT1↓, 2,   SIRT1↑, 2,   Warburg↓, 2,  

Cell Death ⓘ

Akt↓, 9,   p‑Akt↓, 3,   APAF1↑, 1,   Apoptosis↑, 15,   ASK1↑, 1,   Bak↑, 2,   BAX↑, 10,   BAX⇅, 1,   Bax:Bcl2↑, 4,   Bcl-2↓, 11,   Bcl-xL↓, 7,   BIM↓, 1,   BIM↑, 2,   Casp↑, 5,   Casp1↓, 1,   Casp12?, 1,   Casp12↑, 1,   Casp3↓, 1,   Casp3↑, 14,   Casp7↑, 1,   Casp8↑, 3,   Casp9↑, 8,   cl‑Casp9↑, 1,   cFLIP↓, 2,   CK2↓, 1,   Cyt‑c↑, 11,   Cyt‑c↝, 1,   Diablo↑, 2,   DR5↑, 2,   Fas↑, 1,   FasL↑, 1,   HGF/c-Met↓, 1,   hTERT/TERT↓, 5,   IAP1↓, 2,   IAP2↓, 1,   iNOS↓, 2,   JNK↓, 1,   JNK↑, 2,   p‑JNK↑, 1,   MAPK↓, 5,   MAPK↑, 1,   Mcl-1↓, 3,   Mcl-1↑, 1,   MDM2↑, 1,   p‑MDM2↓, 1,   NOXA↑, 1,   p27↑, 5,   p38↑, 2,   p‑p38↑, 2,   PUMA↑, 1,   survivin↓, 7,   Telomerase↓, 4,   TRAIL↑, 1,   TumCD↑, 1,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction ⓘ

cSrc↓, 1,   EF-1α↓, 1,   HCAR2↑, 3,   HER2/EBBR2↓, 1,  

Transcription & Epigenetics ⓘ

cJun↑, 2,   EZH2↓, 1,   H3↓, 1,   H3↑, 1,   ac‑H3↑, 4,   H4↓, 1,   H4↑, 1,   ac‑H4↑, 3,   HATs↓, 1,   HATs↑, 2,   miR-30a-5p↑, 1,   other?, 1,   pRB↑, 1,   tumCV↓, 1,  

Protein Folding & ER Stress ⓘ

ChemChap↑, 1,   CHOP↑, 3,   cl‑CHOP↑, 1,   eIF2α↑, 1,   p‑eIF2α↑, 2,   ER Stress↓, 1,   ER Stress↑, 6,   GRP78/BiP↓, 1,   GRP78/BiP↑, 3,   HSP27↑, 1,   p‑PERK↑, 1,   UPR↑, 1,   XBP-1↓, 1,  

Autophagy & Lysosomes ⓘ

ATG3↑, 1,   ATG5↑, 1,   Beclin-1↑, 1,   LAMP2↑, 1,   LC3‑Ⅱ/LC3‑Ⅰ↑, 1,   LC3II↑, 3,   p62↓, 1,   p62↑, 1,   TumAuto↑, 2,  

DNA Damage & Repair ⓘ

BRCA1↑, 1,   DNAdam↑, 5,   DNArepair↓, 1,   DNMT1↓, 3,   DNMT3A↓, 2,   DNMTs↓, 6,   GADD45A↑, 1,   p16↑, 2,   P53↑, 9,   PARP↓, 1,   PARP↑, 2,   cl‑PARP↑, 6,   PARP1↑, 1,   PCNA↓, 6,  

Cell Cycle & Senescence ⓘ

CDK1↑, 1,   CDK2↓, 5,   CDK4↓, 5,   Cyc↓, 1,   cycA1/CCNA1↓, 1,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 10,   cycD1/CCND1↑, 1,   CycD3↓, 1,   cycE/CCNE↓, 1,   P21?, 1,   P21↑, 9,   p‑RB1↓, 2,   TumCCA↓, 1,   TumCCA↑, 15,  

Proliferation, Differentiation & Cell State ⓘ

ALDH↓, 1,   ALDH1A1↓, 1,   CD133↓, 3,   CD34↓, 1,   CD44↓, 2,   cFos↑, 1,   p‑cMET↑, 1,   cMYB↓, 1,   CSCs↓, 3,   EMT↓, 9,   ERK↓, 5,   ERK↑, 2,   p‑ERK↓, 2,   p‑ERK↑, 1,   FOXO↑, 1,   FOXO3↓, 1,   FOXO3↑, 1,   Gli↓, 1,   GSK‐3β↓, 1,   GSK‐3β↑, 1,   HDAC↓, 46,   HDAC1↓, 3,   HDAC2↓, 1,   HDAC3↓, 2,   HDAC4↓, 1,   HMGCR↓, 1,   HMTs↓, 1,   IGF-1↓, 3,   IGFBP3↑, 1,   Let-7↑, 1,   mTOR↓, 5,   p‑mTOR↓, 1,   mTORC1↓, 1,   Nanog↓, 2,   Nestin↓, 2,   NOTCH↓, 2,   NOTCH1↓, 2,   NOTCH1↑, 1,   NOTCH3↓, 1,   OCT4↓, 2,   PI3K↓, 6,   p‑PI3K↓, 1,   PTEN↓, 1,   PTEN↑, 5,   p‑PTEN↓, 1,   RAS↓, 1,   RAS↑, 1,   Shh↓, 1,   SOX2↓, 1,   p‑Src↓, 1,   STAT3↓, 8,   p‑STAT3↓, 2,   p‑STAT3↑, 1,   STAT5↓, 1,   p‑STAT6↓, 1,   TOP1↓, 1,   TumCG↓, 3,   Wnt↓, 2,  

Migration ⓘ

AntiAg↓, 1,   AP-1↓, 2,   AXL↓, 1,   Ca+2↑, 3,   CD31↓, 1,   Cdc42↓, 1,   CDKN1C↑, 1,   CEA↓, 1,   CLDN1↓, 3,   CLDN2↓, 1,   CXCL12↓, 1,   E-cadherin↓, 1,   E-cadherin↑, 6,   FAK↓, 5,   p‑FAK↑, 1,   Fibronectin↓, 1,   ITGB1↓, 1,   Ki-67↓, 2,   MET↓, 1,   p‑MET↓, 1,   MMP-10↓, 1,   MMP1↓, 1,   MMP2↓, 9,   MMP9↓, 7,   MMPs↓, 8,   MUC4↓, 1,   N-cadherin↓, 3,   PDGF↓, 1,   PKCδ↓, 1,   Rac1↓, 1,   Rho↓, 1,   Slug↓, 1,   Snail↓, 3,   SOX4↓, 1,   TET1↑, 1,   TGF-β↓, 1,   TIMP2↑, 1,   Treg lymp↓, 1,   TSP-1↑, 1,   TumCA↑, 1,   TumCI↓, 2,   TumCMig↓, 4,   TumCP↓, 5,   TumMeta↓, 8,   TumMeta↑, 1,   Twist↓, 6,   Tyro3↓, 1,   uPA↓, 4,   Vim↓, 3,   Vim↑, 1,   Zeb1↓, 3,   ZO-1↑, 1,   β-catenin/ZEB1↓, 5,   β-catenin/ZEB1↑, 1,  

Angiogenesis & Vasculature ⓘ

angioG↓, 14,   EGFR↓, 4,   EGFR↑, 1,   HIF-1↓, 1,   Hif1a↓, 12,   LOX1↓, 1,   NO↓, 1,   NO↑, 1,   VEGF↓, 15,   VEGFR2↓, 4,  

Barriers & Transport ⓘ

GLUT1↓, 2,   P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

ASC↓, 1,   COX2↓, 9,   COX2↑, 2,   CXCR4↓, 3,   HCAR2↑, 3,   ICAM-1↓, 1,   IFN-γ↑, 2,   Igs↑, 1,   IKKα↓, 2,   IL10↓, 3,   IL10↑, 1,   IL1β↓, 3,   IL2↑, 4,   IL6↓, 5,   IL8↓, 1,   Imm↑, 1,   Inflam↓, 4,   JAK2↓, 1,   M2 MC↓, 1,   MDSCs↓, 1,   NF-kB↓, 14,   NK cell↑, 1,   p65↓, 1,   p‑p65↓, 1,   PD-1↓, 1,   PGE2↓, 2,   PSA↓, 1,   TLR4↓, 1,   TNF-α↓, 4,  

Protein Aggregation ⓘ

NLRP3↓, 3,  

Hormonal & Nuclear Receptors ⓘ

AR↓, 2,   CDK6↓, 3,   ER(estro)↓, 1,  

Drug Metabolism & Resistance ⓘ

BioAv↓, 3,   BioAv↑, 5,   BioAv↝, 1,   BioEnh↑, 1,   ChemoSen↑, 15,   Dose?, 2,   Dose↝, 8,   eff↓, 3,   eff↑, 24,   eff↝, 2,   eff∅, 1,   Half-Life↓, 2,   Half-Life↝, 1,   P450↓, 1,   RadioS↑, 6,   selectivity↑, 9,  

Clinical Biomarkers ⓘ

ALAT↓, 2,   ALP↓, 2,   AR↓, 2,   AST↓, 1,   BG↓, 1,   BMPs↑, 1,   BRCA1↑, 1,   CEA↓, 1,   EGFR↓, 4,   EGFR↑, 1,   EZH2↓, 1,   GutMicro↑, 3,   HER2/EBBR2↓, 1,   hTERT/TERT↓, 5,   IL6↓, 5,   Ki-67↓, 2,   LDH↓, 1,   Maspin↑, 1,   NSE↓, 1,   PSA↓, 1,  

Functional Outcomes ⓘ

AntiCan↑, 7,   cachexia↓, 1,   cardioP↑, 2,   CardioT↓, 1,   chemoP↑, 5,   chemoPv↑, 5,   ChemoSideEff↓, 3,   hepatoP↑, 5,   neuroP↑, 7,   OS↑, 4,   Remission↑, 1,   RenoP↑, 3,   Risk↓, 3,   toxicity↓, 3,   TumVol↓, 2,   Weight↓, 1,  

Infection & Microbiome ⓘ

CD8+↑, 1,  
Total Targets: 396

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress ⓘ

antiOx↑, 6,   Catalase↑, 5,   GPx↑, 3,   GSH↑, 3,   GSTA1↑, 1,   GSTs↑, 2,   HDL↑, 1,   HO-1↑, 1,   lipid-P↓, 1,   MDA↓, 1,   NQO1↑, 1,   NRF2↑, 2,   ROS↓, 10,   ROS↝, 1,   SAM-e↑, 1,   SOD↑, 4,  

Mitochondria & Bioenergetics ⓘ

ATP↝, 1,  

Core Metabolism/Glycolysis ⓘ

ALAT↓, 1,   NAD↑, 1,   NAD↝, 1,   NADPH↓, 1,   SIRT1↑, 1,  

Cell Death ⓘ

Casp3↓, 2,   iNOS↓, 1,   MAPK↓, 1,  

Transcription & Epigenetics ⓘ

other↑, 1,  

Proliferation, Differentiation & Cell State ⓘ

HDAC↓, 1,   HDAC3↓, 1,   PTEN↑, 1,  

Migration ⓘ

Ca+2↝, 1,   Ki-67↓, 1,   p‑Rac1↓, 1,   serineP↓, 1,  

Angiogenesis & Vasculature ⓘ

NO↓, 1,   VEGF↑, 1,  

Barriers & Transport ⓘ

BBB↑, 1,   P-gp↓, 1,  

Immune & Inflammatory Signaling ⓘ

COX2↓, 2,   CRP↓, 1,   CXCR2↑, 1,   IFN-γ↓, 1,   IKKα↑, 1,   IL10↓, 1,   IL10↑, 3,   IL17↓, 1,   IL1β↓, 3,   IL6↓, 4,   IL8↓, 1,   Inflam↓, 8,   Inflam↑, 1,   NF-kB↓, 4,   PGE2↓, 1,   TNF-α↓, 6,   TNF-β↑, 1,   VitD↑, 1,  

Hormonal & Nuclear Receptors ⓘ

testos↑, 1,  

Drug Metabolism & Resistance ⓘ

BioAv?, 1,   BioAv↓, 4,   BioAv↑, 1,   Dose↑, 1,   Dose↝, 1,   eff↑, 3,   Half-Life↝, 1,   Half-Life∅, 1,   P450↓, 1,   selectivity↑, 1,  

Clinical Biomarkers ⓘ

ALAT↓, 1,   ALP↓, 1,   AST↓, 2,   BMD↑, 1,   BMPs↑, 1,   Calcium↑, 1,   CRP↓, 1,   GutMicro↑, 1,   hs-CRP↓, 1,   IL6↓, 4,   Ki-67↓, 1,   Mag↑, 1,   VitD↑, 1,  

Functional Outcomes ⓘ

AntiCan↑, 1,   cardioP↑, 1,   chemoP↑, 1,   chemoPv↑, 1,   ChemoSideEff↓, 1,   cognitive↑, 1,   hepatoP↑, 1,   memory↑, 1,   neuroP↑, 3,   radioP↑, 1,   RenoP↑, 1,   Risk↓, 1,   toxicity↝, 1,   toxicity∅, 2,  
Total Targets: 93

Scientific Paper Hit Count for: HDAC, Histone deacetylases
9 Sulforaphane (mainly Broccoli)
5 Thymoquinone
4 Butyrate
4 Phenylbutyrate
3 Boron
2 Apigenin (mainly Parsley)
2 Chrysin
2 Honokiol
2 Propolis -bee glue
2 Quercetin
1 3-bromopyruvate
1 Atorvastatin
1 Berberine
1 Betulinic acid
1 Curcumin
1 diet FMD Fasting Mimicking Diet
1 Chemotherapy
1 EGCG (Epigallocatechin Gallate)
1 Luteolin
1 Phenethyl isothiocyanate
1 Silymarin (Milk Thistle) silibinin
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:26  Cells:%  prod#:%  Target#:140  State#:%  Dir#:1
  wNotes=0  sortOrder:rid,rpid

 

Home Page